Evidence map›Paper›PMID 37178816›Full record

ArticleJournal of vascular and interventional radiology : JVIR2023

Stimulating Antitumoral Immunity by Percutaneous Cryoablation and Combination Immunoadjuvant Therapy in a Murine Model of Hepatocellular Carcinoma.

Tyler Mandt, Amandip Bangar, Consuelo Sauceda, Manasi Das, Carolyn Moderbacher, Mansur Ghani, Nicholas Webster, Isabel Newton

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of vascular and interventional radiology : JVIR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Tyler MandtHealth Department of Radiology, University of California San Diego, San Diego.
Amandip BangarHealth Department of Radiology, University of California San Diego, San Diego.
Consuelo SaucedaHealth Department of Radiology, University of California San Diego, San Diego.
Manasi DasHealth Department of Radiology, University of California San Diego, San Diego.
Carolyn ModerbacherLa Jolla Institute for Allergy and Immunology, La Jolla, California.
Mansur GhaniHealth Department of Radiology, University of California San Diego, San Diego.
Nicholas WebsterSan Diego Veteran's Affairs, University of California San Diego, San Diego.
Isabel NewtonSan Diego Veteran's Affairs, University of California San Diego, San Diego. Electronic address: inewton@health.ucsd.edu.
UC San Diego Health System · USLa Jolla Institute for Immunology · USUniversity of California San Diego · USUniversity of San Diego · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Traning Clinical Scientists in Radiological ImagingT32EB005970 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Eric Y Chang, Rebecca Ann Rakow-Penner · 2007 to 2026
$3.2M
BLRD VA I01 BX004848BLRD VA IK6 BX005224NCI NIH HHS P30 CA023100NIBIB NIH HHS T32 EB005970
6 · The paper itself

Abstract

purposeTo test the hypothesis that antitumoral immunity can be induced after cryoablation (cryo) of hepatocellular carcinoma (HCC) through coadministration of the immunostimulant CpG and an immune checkpoint (programmed cell death 1 [PD-1]) inhibitor. MATERIALS AND

methodsSixty-three immunocompetent C57BL/6J mice were generated with 2 orthotopic HCC tumor foci: 1 for treatment and 1 to observe for antitumoral immunity. Tumors were treated with incomplete cryo alone or intratumoral CpG and/or a PD-1 inhibitor. The primary endpoint was death or when the following criteria for sacrifice were met: tumor > 1 cm (determined using ultrasound) or moribund state. Antitumoral immunity was assessed using flow cytometry and histology (tumor and liver) as well as enzyme-linked immunosorbent assay (serum). Analysis of variance was used for statistical comparisons.

resultsAt 1 week, the nonablated satellite tumor growth was reduced by 1.9-fold (P = .047) in the cryo + CpG group and by 2.8-fold (P = .007) in the cryo + CpG + PD-1 group compared with that in the cryo group. Compared with cryo alone, the time to tumor progression to endpoints was also prolonged for cryo + CpG + PD-1 and cryo + CpG mice, with log-rank hazard ratios of 0.42 (P = .031) and 0.27 (P < .001), respectively. Flow cytometry and histology showed increased cytotoxic T-cell infiltration (P = .002) and serum levels of the proinflammatory cytokine interferon-γ (P = .015) in tumors and serum of cryo + CpG mice compared with those in tumors and serum of mice treated with cryo alone. High serum levels of the anti-inflammatory cytokine tumor growth factor-β and the proangiogenesis chemokine C-X-C motif chemokine ligand 1 were correlated with a shorter time to endpoints and faster tumor growth.

conclusionsCryo combined with the immunostimulant CpG promoted cytotoxic T-cell infiltration into tumors, slowed tumor growth, and prolonged the time to progression to endpoints in an aggressive murine HCC model.

Indexed as

Carcinoma, HepatocellularCryosurgeryLiver NeoplasmsAdjuvants, ImmunologicAnimalsCell Line, TumorCytokinesDisease Models, AnimalMiceMice, Inbred C57BLProgrammed Cell Death 1 ReceptorAdjuvants, ImmunologicCytokinesProgrammed Cell Death 1 Receptor

Identifiers

PMID37178816
PMCPMC10852103
OpenAlexW4376126952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.